Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the following new medicine which was referred to the Minister of Health under the provisions of section 24(5) of the Act and is set out in the Schedule hereto:
Schedule
Product: Cancidas
Active Ingredient: Caspofungin acetate 60.6mg equivalent to 50mg caspofungin anhydrous free base
Dosage Form: Powder for infusion
New Zealand Sponsor: Merck Sharp & Dohme (New Zealand) Limited
Manufacturers: Catalent Pharma Solutions LLC, Albuquerque, New Mexico, United States of America
Merck & Co Inc, West Point, Pennsylvania, United States of America
Product: Cancidas
Active Ingredient: Caspofungin acetate 83.9mg equivalent to 70mg caspofungin anhydrous free base
Dosage Form: Powder for infusion
New Zealand Sponsor: Merck Sharp & Dohme (New Zealand) Limited
Manufacturers: Catalent Pharma Solutions LLC, Albuquerque, New Mexico, United States of America
Merck & Co Inc, West Point, Pennsylvania, United States of America
Dated this 12th day of September 2008.
ANTHONY HILL, Deputy Director-General, Sector Accountability and Funding Directorate (pursuant to delegation given by the Minister of Health on 6 July 2001).